Skip to main content

Advertisement

SpringerLink
Log in

Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

  • Original Article
  • Published:
Journal of General Internal Medicine Aims and scope Submit manuscript

Abstract

Background

The use of androgen deprivation therapy (ADT) for prostate cancer has increased substantially in recent years, exposing more men to potential treatment complications, including osteoporosis and fractures.

Objective

To determine whether men treated with ADT for prostate cancer received osteoporosis screening, prevention, or treatment.

Design

Cross-sectional observational study using a retrospective review of electronic medical records.

Subjects

One hundred seventy-four patients with prostate cancer on ADT or status-post orchiectomy enrolled in primary care at the New Mexico Veterans Affairs Health Care System as of July 2005.

Measurements

Patient demographics, tumor characteristics (Gleason score, stage, last PSA value, documented bone metastases), history of hip or vertebral fracture, osteoporosis risk factors (number of ADT shots, diabetes, smoking, heavy alcohol use or prescriptions for corticosteroids, thyroid hormone or dilantin). We defined recommended management as performing DXA scans or prescribing bisphosphonates, calcitonin, calcium or vitamin D.

Results

Just 60 of 174 (34%) patients received recommended osteoporosis management based on DXA scans (13%) or treatment with oral or IV bisphosphonates (21%), calcitonin (1%), calcium (16%) or vitamin D (10%). On multivariate analysis, bone metastases, higher last PSA, and younger age at diagnosis were associated with recommended management, whereas Hispanic race/ethnicity was inversely associated.

Conclusions

Most men treated with ADT for prostate cancer did not receive osteoporosis screening, prevention or treatment. Evidence for advanced cancer though not risk factors for osteoporosis or fracture—was associated with receiving osteoporosis management. Further research is needed to identify optimal strategies for screening, prevention, and treatment in this population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56:106–30.

    PubMed  Google Scholar 

  2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238–44.

    Article  PubMed  CAS  Google Scholar 

  3. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–9.

    Article  PubMed  Google Scholar 

  4. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002;60(Suppl 3A):7–12.

    Article  PubMed  CAS  Google Scholar 

  5. Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361–7.

    Article  PubMed  Google Scholar 

  6. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181–6.

    Article  PubMed  CAS  Google Scholar 

  7. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998;83:1561–6.

    Article  PubMed  CAS  Google Scholar 

  8. Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer. 2001;92:1444–50.

    Article  PubMed  CAS  Google Scholar 

  9. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 1995;57:97–9.

    Article  PubMed  CAS  Google Scholar 

  10. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656–61.

    Article  PubMed  CAS  Google Scholar 

  11. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–12.

    Article  PubMed  CAS  Google Scholar 

  12. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948–55.

    Article  PubMed  CAS  Google Scholar 

  13. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005;16:707–11.

    Article  PubMed  CAS  Google Scholar 

  14. Oefelein MG, Ricchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166:1724–8.

    Article  PubMed  CAS  Google Scholar 

  15. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175:136–9.

    Article  PubMed  CAS  Google Scholar 

  16. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897–903.

    Article  PubMed  CAS  Google Scholar 

  17. Melton LJ, 3rd, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H. Fracture risk following bilateral orchiectomy. J Urol. 2003;169:1747–50.

    Article  PubMed  Google Scholar 

  18. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353:878–82.

    Article  PubMed  CAS  Google Scholar 

  19. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162:2217–22.

    Article  PubMed  Google Scholar 

  20. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005–7.

    Article  PubMed  Google Scholar 

  21. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100:892–9.

    Article  PubMed  Google Scholar 

  22. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am. 2004;31:331–52.

    Article  PubMed  Google Scholar 

  23. Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003;97(3 Suppl):789–95.

    Article  PubMed  Google Scholar 

  24. Bae DC, Stein BS. The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol. 2004;172:2137–44.

    Article  PubMed  CAS  Google Scholar 

  25. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005;103:237–41.

    Article  PubMed  Google Scholar 

  26. Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum. 2002;46:3136–42.

    Article  PubMed  Google Scholar 

  27. Solomon DH, Finkelstein JS, Katz JN, Mogun H, Avorn J. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med. 2003;115:398–400.

    Article  PubMed  Google Scholar 

  28. Feldstein A, Elmer PJ, Orwoll E, Herson M, Hillier T. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med. 2003;163:2165–72.

    Article  PubMed  Google Scholar 

  29. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998;158:1789–95.

    Article  PubMed  CAS  Google Scholar 

  30. Krupski TL, Smith MR, Lee WC, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004;101:541–9.

    Article  PubMed  Google Scholar 

  31. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–64.

    Article  PubMed  CAS  Google Scholar 

  32. Morris CA, Cabral D, Cheng H, et al. Patterns of bone mineral density testing: current guidelines, testing rates, and interventions. J Gen Intern Med. 2004;19:783–90.

    Article  PubMed  Google Scholar 

  33. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10 Suppl):S1–34.

    PubMed  Google Scholar 

  34. Writing Group for the ISCD Position Development Conference. Indications and reporting for dual-energy x-ray absorptiometry. J Clin Densitom. 2004;7:37–44.

    Google Scholar 

  35. Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006;81:662–72.

    PubMed  CAS  Google Scholar 

  36. Gourlay M, Richy F, Reginster JY. Strategies for the prevention of hip fracture. Am J Med. 2003;115:309–17.

    Article  PubMed  Google Scholar 

  37. Solomon DH, Connelly MT, Rosen CJ, et al. Factors related to the use of bone densitometry: survey responses of 494 primary care physicians in New England. Osteoporos Int. 2003;14:123–9.

    PubMed  CAS  Google Scholar 

  38. Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002;77:334–8.

    PubMed  Google Scholar 

  39. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604–10.

    Article  PubMed  CAS  Google Scholar 

  40. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004;24:110–3.

    Article  PubMed  CAS  Google Scholar 

  41. Saad F, Gleason DM, Murray R, et al., Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–68.

    PubMed  CAS  Google Scholar 

  42. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416–24.

    PubMed  Google Scholar 

  43. Mazanec D. Osteoporosis screening: time to take responsibility. Arch Intern Med. 2004;164:1047–8.

    Article  PubMed  Google Scholar 

  44. Field MH. Fractures, osteoporosis, and the endocrinologist. Arch Intern Med. 2003;163:2796.

    Article  PubMed  Google Scholar 

  45. Kiebzak GM. Fractures, osteoporosis, and the endocrinologist. In reply. Arch Intern Med. 2003;163:2796–7.

    Article  Google Scholar 

  46. Braga-Basaria M, Basaria S. Preventing skeletal complications in androgen deprived men with prostate cancer: time for action. J Endocrinol Invest. 2006;29:467–70.

    PubMed  CAS  Google Scholar 

  47. Gourlay M. Osteoporosis management: out of subspecialty practice and into primary care. Am Fam Phys. 2004;70:1219–20.

    Google Scholar 

  48. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56.

    Article  PubMed  CAS  Google Scholar 

  49. Cuddihy MT, Amadio PC, Melton LJ 3rd. Patient barriers to osteoporosis interventions after fracture. Mayo Clin Proc. 2002;77:875.

    Article  PubMed  Google Scholar 

  50. Backett-Milburn K, Parry O, Mauthner N. ‘I’ll worry about that when it comes along’: osteoporosis, a meaningful issue for women at mid-life? Health Educ Res. 2000;15:153–62.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Veterans Affairs VISN 18 New Investigator Program and the New Mexico VA Health Care System. The investigators wish to thank Anders Hsi and Danny Garcia for their assistance with this project. The paper was presented at the 2006 Society of General Internal Medicine 29th Annual Meeting on April 27, 2006. The views expressed in this paper are those of the authors and do not necessarily represent the positions or policies of the Department of Veterans Affairs.

Conflicts of Interest

None disclosed.

Author information

Authors and Affiliations

  1. Department of Medicine, New Mexico Veterans Affairs Health Care System, Albuquerque, NM, USA

    Ellen F. T. Yee MD, MPH, Glen H. Murata MD, Christine Handanos MD & Richard M. Hoffman MD, MPH

  2. Lovelace Clinic Foundation, Albuquerque, NM, USA

    Robert E. White MD, MPH

  3. University of New Mexico School of Medicine, Albuquerque, NM, 87108, USA

    Ellen F. T. Yee MD, MPH, Glen H. Murata MD, Christine Handanos MD & Richard M. Hoffman MD, MPH

Authors
  1. Ellen F. T. Yee MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert E. White MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Glen H. Murata MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christine Handanos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Richard M. Hoffman MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ellen F. T. Yee MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yee, E.F.T., White, R.E., Murata, G.H. et al. Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation Therapy. J GEN INTERN MED 22, 1305–1310 (2007). https://doi.org/10.1007/s11606-007-0291-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11606-007-0291-4

KEY WORDS

Search

Navigation